



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



10 MAY 2021

FDA ADVISORY  
No. **2021-1006**

TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT : Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:

1. OTC Tylenol® Cold 10 Caplets [*Label in foreign language*]
2. Azithromycin Tablets – Aqimeisu Pian 0.25g [*as reflected in the package insert*]
3. Jingkang Jiaonang
4. OTC HOMESUN Ketotifen Fumarate Tablets 60 Tablets
5. Ceftriaxone Sodium for Injection 1.0g [*Label in foreign language*]

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:



Figure 1. Unregistered drug product



易今康® 国药准字H20064320

# 阿奇霉素片

【适应症】

1. 化脓性链球菌引起的急性咽炎、急性扁桃体炎。
2. 敏感细菌引起的鼻窦炎、中耳炎、急性支气管炎、慢性支气管炎急性发作。
3. 肺炎链球菌、流感嗜血杆菌以及肺炎支原体所致的肺炎。
4. 沙眼衣原体及非多种耐药淋病奈瑟菌所致的尿道炎和宫颈炎。
5. 敏感细菌引起的皮肤软组织感染。

0.25g×6片




Azithromycin Tablets – Aqimeisu Pian 0.25g [as reflected in the package insert]

Figure 2. Unregistered drug product

龙仕康® 国药准字Z20090219

# 颈康胶囊

JingKangJiaoNang

补肾、活血、止痛。用于肾虚血瘀所致的颈椎病。  
 症见：颈项疼痛麻木、活动不利、头晕耳鸣等。

18粒×1板/盒  
 吉林真元制药有限公司



Jingkang Jiaonang

Figure 3. Unregistered drug product



Figure 4. Unregistered drug product



Figure 5. Unregistered drug product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee its quality, safety and efficacy. Therefore, consumption of such violative products may pose potential danger or injury to health.

Pursuant to Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at [info@fda.gov.ph](mailto:info@fda.gov.ph). To report continuous sale or distribution of unregistered health products, kindly e-mail us via [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph). You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General

DTN:   
20210426124910